General Information of Drug Combination (ID: DCA89CV)

Drug Combination Name
SY-1425 Taxol
Indication
Disease Entry Status REF
High grade ovarian serous adenocarcinoma Investigative [1]
Component Drugs SY-1425   DMH8UF0 Taxol   DMUOT9V
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: OVCAR-8
Zero Interaction Potency (ZIP) Score: 14.07
Bliss Independence Score: 14.88
Loewe Additivity Score: 1.54
LHighest Single Agent (HSA) Score: 14.91

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [2]
Myelodysplastic syndrome 2A37 Phase 1 [2]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [2]
------------------------------------------------------------------------------------
Indication(s) of Taxol
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [3]
Solid tumour/cancer 2A00-2F9Z Approved [4]
Pancreatic cancer 2C10 Phase 3 [2]
Gastric adenocarcinoma 2B72 Phase 2 [5]
Ovarian cancer 2C73 Phase 2 [5]
Taxol Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Apoptosis regulator Bcl-2 (BCL-2) TTJGNVC BCL2_HUMAN Modulator [3]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCUHV1X HL-60(TB) Investigative [6]
Chronic myelogenous leukemia DC46IBE K-562 Investigative [6]
Clear cell renal cell carcinoma DCEUG0B A498 Investigative [6]
Clear cell renal cell carcinoma DCTY9JT 786-0 Investigative [6]
Clear cell renal cell carcinoma DCK4XFJ CAKI-1 Investigative [6]
Glioblastoma DCDPXWY SNB-75 Investigative [6]
Glioma DCIJ8WD SF-295 Investigative [6]
Glioma DC9FD1U SF-268 Investigative [6]
Papillary renal cell carcinoma DCGF0X1 ACHN Investigative [6]
Plasma cell myeloma DCJMAX6 RPMI-8226 Investigative [6]
Renal cell carcinoma DCB5EZV UO-31 Investigative [6]
Breast adenocarcinoma DC4WN0A MDA-MB-468 Investigative [7]
Carcinoma DC60YAW MCF7 Investigative [7]
Colon carcinoma DCSZ8BO KM12 Investigative [7]
Invasive ductal carcinoma DCQP3LK BT-549 Investigative [7]
Invasive ductal carcinoma DCAMS9D HS 578T Investigative [7]
Invasive ductal carcinoma DCK989Q T-47D Investigative [7]
Adenocarcinoma DCAA956 A549 Investigative [1]
Adenocarcinoma DCCN6KQ HCC-2998 Investigative [1]
Large cell lung carcinoma DCG9FXT NCI-H460 Investigative [1]
Lung adenocarcinoma DCS6OK2 MDA-MB-231 Investigative [1]
Melanoma DCX9A17 MALME-3M Investigative [1]
Mixed endometrioid and clear cell carcinoma DCDX22C IGROV1 Investigative [1]
Prostate carcinoma DCKS9T0 PC-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 24 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
7 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.